Navigation Links
Avicena to Advance Huntington's Disease Clinical Program into Phase III

Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today the selection of the optimal dose of HD-02, its novel drug candidate for the treatment of Huntington's Disease.

This dose was determined in an open-label dose escalation study, led by Dr. Steven Hersch and Dr. Diana Rosas of Massachusetts General Hospital (MGH), and will be further evaluated in a Phase III clinical trial.

The dose escalation study evaluated HD-02 in a range of doses from 10 to 40 grams per day and successfully determined the optimal dose that provided the maximum efficacy, safety and tolerability. The full scope of the data will be disseminated upon the results being peer reviewed.

Based on these findings, Avicena and its collaborators Dr. Hersch and the Huntington Study Group have developed a double-blind, placebo-controlled Phase III clinical trial anticipated to commence in early 2008. The Phase III trial will be one of the single largest trials for Huntington's patients, with external funding to be announced.

Upon commencement of this clinical trial, Avicena will have advanced three different indications into phase III trials that include some of the largest trial to date in both Parkinson's and Huntington's.

"We are very encouraged by the results of our HD-02 trial and we believe that in conjunction with our collaborators at MGH, we have identified the optimal dose as we move forward to validate HD-02 as a potential treatment for Huntington's disease, for which there is no current approved drug by the FDA.

We are committed to developing therapeutics that we hope can slow the progression of neurodegenerative diseases," stated Belinda Tsao-Nivaggioli, CEO of Avicena.

"We are excited by the results of our studies with HD-02 to date. This Phase III study will evaluat
'"/>




Page: 1 2

Related medicine news :

1. Advances in Treatment of Cataracts
2. Advanced STD programs required
3. Hope For Patients With Advanced Breast Cancer
4. Advances In Stem Cells Research
5. Breast Cancer Advance
6. Canadian Lung Cancer Study Lauded As Major Advance in Cancer Fight
7. Speedier Access To Advances In Breast Cancer Sought For Patients
8. HIV Vaccine Field Trials In Advanced Stage
9. Advance Funeral For AIDS-infected South African
10. New Screening Techniques to Lead Advances In Pain Therapy
11. Twin Treatment Could Be Used Increase Survival Rates In Advanced Melanoma
Post Your Comments:
(Date:5/18/2013)... Orlando, FL (May 18, 2013) A ground-breaking ... colorectal care, according to research presented today at ... optimizing the minimal withdrawal time for colonoscopies and ... , During colonoscopy, doctors use a device called ... test for colorectal cancer allows a doctor to ...
(Date:5/18/2013)... New York (PRWEB) May 18, 2013 ... pelvic mesh products continue to move forward in a ... Court, Bernstein Liebhard LLP reports. According to a notice ... in the Ethicon pelvic mesh litigation will be held ... 2,755 complaints have been filed in the proceeding on ...
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) -- ... drink, but new research shows that college women are more ... basis than are college men. Much of this ... safe on a weekly basis is much lower for women ... 14 for men. But, there,s good reason for that difference. ...
(Date:5/18/2013)... After working diligently for months and putting in ... the integration of the fitment specs for the redesigned 2012 ... stun the automobile market with its extraordinary features and unique ... as the latest entry in the size it up ... the year 2013. , Aptly suiting its name, 2012 ...
(Date:5/18/2013)... 2013 Family Magazine of Washington DC was ... Follow Media Consulting, Inc. in the category of Summer ... and dedication of the areas best in the ultimate guide ... parenting better than Brenda Hyde, a mother of four and ... know about the vast resources available to them in the ...
Breaking Medicine News(10 mins):Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2
... suitable treatment mode for women diagnosed with breast cancer who ... should consider hormonal treatments to reduce their risk of a ... study led by researchers at the University of Michigan Comprehensive ... genetic mutation who had their ovaries removed or took the ...
... as a custom rather than as a matter of choice. ... waywardness //in the females while some clans even consider it ... initiating teenage girls into adulthood. ,As tradition goes ... which are often unsterilized. In addition the area of excision ...
... in regulating cell death, a Queen’s University study has found. ... be used to promote cell death in cancer cells but ... in neuronal cells in the case of Alzheimer’s or Parkinson’s. ... Medicine with the Cancer Biology and Genetics division of Queen’s ...
... new survey nearly 12 million Americans are affected by peripheral ... arteries are blocked that brings blood to the legs due ... is likely to increase in the coming decades and it’s ... drugs to treat it. , ,By examining the physiology ...
... sector educational group Amity Institutions have decided to launch ... plans to set up academic and training infrastructure in ... in an effort to expand the educational facilities in ... President, and board member of Ritnand Balved Education Foundation, ...
... the breast cancer in younger black women nothing significant has ... women the number of black women affected by breast cancer ... the black women is much higher when compared with the ... 50 have a 77 percent of mortality rate. ...
Cached Medicine News:Health News:Breast-Sparing Surgery: An Optional Treatment Mode For Women With Breast Cancer 2Health News:Breast-Sparing Surgery: An Optional Treatment Mode For Women With Breast Cancer 3Health News:Female Circumcision Rampant in Africa 2Health News:Protein’s role in regulating cell death sets direction for Alzheimer’s, Parkinson’s and cancer resea 2Health News:New Test to Diagnose the Peripheral Arterial Disease (PAD) 2Health News:Breast Cancer Mortality Rate is Higher Among Black Women 2Health News:Breast Cancer Mortality Rate is Higher Among Black Women 3
(Date:5/17/2013)... 2013  Sorrento Therapeutics, Inc. (OTCBB: SRNE; or ... Small Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) ... Diseases (NIAID), a division of the National Institutes ... human antibody therapeutics to combat Staphylococcus aureus ... including methicillin-resistant S. aureus (MRSA), was ...
(Date:5/17/2013)... CHAMPAIGN, Ill. , May 17, 2013  Sony ... new Sony SP6800 Spectral Analyzer (SP6800).  Sony will be ... 2013, which will be held at the ... San Diego, California , from May 20 - ... Sony,s second analytical system, incorporating commercial audio-visual technologies into ...
(Date:5/17/2013)... 17, 2013 /PRNewswire-iReach/ -- The escalation of new ... placing renewed emphasis on alternate delivery technologies. Alternate ... number of factors are converging to create both ... their delivery device partners . These include new ... growing trend toward self-administration for chronic diseases, shifting ...
Breaking Medicine Technology:Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3
... , July 16 Warner Chilcott ... received a communication from the U.S. Food & Drug Administration ... delayed-release tablets extending the Prescription Drug User Fee Act (PDUFA) ... additional information solicited by the FDA and previously provided by ...
... , July 15 LyoTechnica, LLC has ... drug development services for injectable pharmaceuticals. The company and ... in lyophilization and liquid dosage form development as well ... of parenteral drugs. The company offers analytical and formulation ...
Cached Medicine Technology:Warner Chilcott Announces 3-Month Extension of PDUFA Date on Next Generation Actonel Product 2Warner Chilcott Announces 3-Month Extension of PDUFA Date on Next Generation Actonel Product 3Formation of Contract Parenteral Drug Development Services Company Announced 2
The Onar®Lp test system is an in vitro test for the qualitative diagnosis of legionella in clinical samples....
The Onar®Lp -QP test system is an in vitro test for the quantitative diagnosis of legionella in clinical samples....
Designed for OSA patients who have difficulty with conventional CPAP therapy, the ResMed SULLIVAN Comfort system is a solution for those who need an alternative to CPAP....
... an approach to treatment that ... pressure range to 25 cm ... treat patients with severe OSA. ... integrated humidification and built-in Encore® ...
Medicine Products: